Protalix BioTherapeutics Inc. (PLX) exhibits 48.8% gross margins and -13.0% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 48.8% gross profitability converts into -10.4% operating margin and -13.0% ROIC, outpacing sector cost of capital.
ROIC: -13.0% // GM: 48.8%YoY revenue trajectory of -1.2% paired with -6.48% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -1.2% // FCF YLD: -6.48%Altman Z-Score of 0.20 and Piotroski F-Score of 2/9 indicate low near-term refinancing stress.
ALTMAN Z: 0.20 // F-SCORE: 2/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $2.61 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend -12.5% net margins.
NET MARGIN: -12.5% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for PLX & activate live FRED threshold breach alerts.